Adding Apalutamide To Adt Effective In High
Intensification of androgen-deprivation therapy with the addition of the androgen receptor inhibitor apalutamide showed potential as a treatment for patients with high-risk biochemically relapsed prostate cancer, according to findings from the phase 3 PRESTO trial presented at the 2022 ESMO Congress. Read more.
Zero John & Amy Phelan And Alec & Kelly Gores Pcf Valor Young Investigator Award
Cedars-Sinai Medical Center
Mentors: Stephen Freedland, MD, Edwin Posadas, MD
A Nationwide VA Study on Systemic Treatment Patterns in Black Patients with Metastatic Castration-Resistant Prostate Cancer
Description:
What this means to patients: Disparities in prostate cancer mortality are a major problem. The contributors to these disparities are multifactorial and complex but include unequal access to health care. Dr. Gong and team will use a large VA data cohort to investigate how differences in treatment patterns and time to treatment initiation contribute to prostate cancer disparities. These findings will support strategies to improve access to standard and novel prostate cancer treatments while ensuring timely initiation of such treatments in Black patients, to reduce prostate cancer disparities.
Chasing Rivals Bayer Files Nubeqa For New Prostate Cancer Use
Bayer has filed for approval to extend the use of its prostate cancer therapy Nubeqa as it tries to achieve labelling parity with rival drugs from Pfizer/Astellas and Johnson & Jonson, and fulfil its aim of 3 billion in peak sales for the drug.
Nubeqa is already making headway in the market as a treatment for non-metastatic, castration resistant prostate cancer , with sales of 219 million last year, but will need to expand into new forms of the disease if it is to meet its commercial objectives.
Part of that will be to include patients with metastatic, hormone-sensitive prostate cancer on the label, a group with more advanced disease that is already treated with blockbuster oral androgen receptor inhibitors like Pfizer/Astellas Xtandi and J& Js Erleada .
The latest filings for Nubeqa in the US and Europe are based on the ARASENS trial which showed that adding the drug to androgen deprivation therapy and docetaxel chemo led to a statistically significant improvement in overall survival compared to ADT plus docetaxel and placebo.
The risk of death was significantly lower by around 33% in the Nubeqa group compared to the placebo group, according to the results, which were in the New England Journal of Medicine in February.
There was also a big increase in the duration of response, from a media of just under 17 months to 41 months.
Dont miss your daily pharmaphorum news.
Don’t Miss: Another Name For Prostate Cancer
Prostate Cancer Treatment: Competition
After Xtandi and Erleada, darolutamide is the third in a line of second-generation anti-androgen hormonal therapies to seek approval for nmCRPC patients. Depending on the market, these drugs are also used to treat other patient subsets, including those with metastatic hormone-sensitive, nonmetastatic castration-resistant, and metastatic castration-resistant prostate cancer .
To provide insight on the near-term nmCRPC segment in the three geographic markets, it was estimated that darolutamide will capture the smallest market share by sales among its competitors by the end of the 20162026 forecast period.
Related
Dont Miss: Medication To Treat Prostate Cancer
Treating Prostate Cancer That Has Spread To The Bones
Doctors are studying the use ofradiofrequency ablation to help control pain in men whose prostate cancer has spread to one or more areas in the bones. During RFA, the doctor uses a CT scan or ultrasound to guide a small metal probe into the area of the tumor. A high-frequency current is passed through the probe to heat and destroy the tumor. RFA has been used for many years to treat tumors in other organs such as the liver, but its use in treating bone pain is still fairly new. Still, early results are promising.
Also Check: Wives Of Prostate Cancer Survivors
The Indicate Study Treating Prostate Cancer That Has Come Back After Surgery With Apalutamide And Targeted Radiation Based On Pet/ct Imaging
Do you have prostate cancer that has returned after prostatectomy? If so, you may be able to participate in this study of potential new treatment approaches. In the EA8191/INDICATE study, all participants will receive the usual treatment for prostate cancer that recurs after surgery, which is radiation therapy to the prostate bed and pelvic lymph nodes, combined with short-term androgen deprivation therapy , also sometimes referred to as hormone therapy. In addition:
Some patients will receive additional PET/CT imaging, depending on the results of their initial PET/CT scan. Some patients will also receive a type of hormone therapy called apalutamide, which is approved by the FDA for treatment of your prostate cancer. Some patients, depending on the results of their initial PET/CT scan, will receive metastasis-directed radiation therapy.
To decide which of these approaches is better, doctors on the study team will be looking to see if your cancer responds, and if it returns again, how much time passes after your treatment before it returns.
To learn more about this study and to find out if you may be eligible, please visit:
ClinicalTrials.gov identifier: NCT04423211
Wild Dunes Mga Pcf Young Investigator Award
Dong-Woo Kang, PhD
Harvard: Dana-Farber Cancer Institute
Mentors: Christina Dieli-Conwright, PhD, MPH, Alicia Morgans, MD, MPH, Timothy Rebbeck, PhD
Exercise for Tumor Suppressive Impact in Black Patients with Prostate Cancer on Active Surveillance: The RE-MOVE Trial
Description:
What this means to patients: Preclinical and epidemiologic studies have suggested that exercise can reduce prostate cancer progression, however few clinical trials have evaluated this. Dr. Kangs project will determine whether aerobic and resistance training can reduce the risk of PSA progression in Black patients with low-risk prostate cancer undergoing active surveillance. This could lead to a new exercise-based intervention that will improve cancer outcomes, physical fitness, and psychological distress in this underrepresented group of cancer patients, which will contribute to reducing prostate cancer disparities.
Read Also: Hot Flashes Prostate Cancer Management
Alnylam On Course For Snagging Label Expansion For Oxlumo
Company: Alnylam, Inc. Type of Application: supplemental new drug applicationCandidate: OxlumoIndication: hyperoxaluria Type 1Date: Oct. 6
Oxlumo, which goes by the generic name lumasiran, an RNAi therapeutic, is being evaluated for the reduction of plasma oxalate in patients with advanced hyperoxaluria type 1 a rare disorder that mainly affects the kidneys due to the accumulation of a substance called oxalate, which is normally filtered through the kidneys and excreted in the urine.
This therapy was first approved in 2020 for lowering urinary oxalate labels in pediatric and adult patients. In the second quarter, it fetched the company $15 million in sales, down only 2% sequentially.
See also: Alzheimers Progression Slowed Down By Biogens New Drug In Late-Stage Study: Analyst Sees 25%
Recommended Reading: Gleason 9 Prostate Cancer Prognosis
With This The German Drugmaker Seeks To Widen The Use Of The Prostate Cancer Drug From An Early Disease Stage To Metastatic Cases
0110
Bayers Nubeqa drug won priority review status from the US Food and Drug Administration , as the German drugmaker seeks to widen the use of the prostate cancer drug from an early disease stage to metastatic cases.
The priority status was granted as the US regulatory body accepted Bayers supplemental New Drug Application for the use of Nubeqa, jointly developed with Finnish drugmaker Orion, against metastatic hormone-sensitive prostate cancer, Bayer said in a statement recently.
Edits by EP News Bureau
Express Pharma, first published as Express Pharma Pulse in 1994, is today Indias leading business fortnightly for the pharmaceutical industry. With the patronage of its readers, Express Pharma has grown to become the No.1 Business News Magazine for the pharmaceutical industry. The editorial contents include: news, views, analysis and interviews, under four main segments: Market , Management , Research and Pharma Life . Besides this, we bring out periodic specials like the quarterly Pharma Technology Review, Packaging Special and LABNEXT.
Also Check: Ga 68 Psma Pet Ct For Prostate Cancer Ppt
Point Biopharma Pcf Young Valor Investigator Award
University of Wisconsin
Mentors: Joshua Lang, MD, Shuang Zhao, MD, MSc, Brett Carver, MD
Elucidating Molecular Correlates of PSMA Expression in Prostate Cancer Liquid Biopsies to Identify Biomarkers of Response and Resistance to PSMA-Targeted Therapies
Description:
- The PI3K pathway is the most commonly mutated tumor-driving pathway in prostate cancer, with mutations occurring in more than 50% of mCRPC. However, clinical efficacy of PI3K pathway inhibitors has been modest, even in patients with PI3K pathway-mutated prostate cancer.
- Early data suggest the newly approved treatment LuPSMA may synergize with PI3K pathway-targeting treatments. LuPSMA is a molecular radiotherapy that targets the prostate cancer-associated protein PSMA.
- Dr. Sharifis project will define the mechanisms by which synergy between LuPSMA or PI3K pathway inhibitors may occur.
- Whether and how PI3K pathway mutations affect PI3K pathway activity and PSMA levels will be investigated.
- Circulating tumor cells from patients on clinical trials will be studied to determine whether they may be useful liquid biopsy biomarkers for determining PI3K pathway status in patients.
- If successful, this project will define the biology of how the PI3K and PSMA pathways intersect, and provide rationale for a precision medicine clinical trial testing the combination of PI3K-inhibitors and LuPSMA.
Physical Emotional And Social Effects Of Cancer
Cancer and its treatment cause physical symptoms and side effects, as well as emotional, social, and financial effects. Managing all of these effects is called palliative care or supportive care. It is an important part of your care that is included along with treatments intended to slow, stop, or eliminate the cancer.
Palliative care focuses on improving how you feel during treatment by managing symptoms and supporting patients and their families with other, non-medical needs. Any person, regardless of age or type and stage of cancer, may receive this type of care. And it often works best when it is started right after a cancer diagnosis. People who receive palliative care along with treatment for the cancer often have less severe symptoms, better quality of life, and report that they are more satisfied with treatment.
Palliative treatments vary widely and often include medication, nutritional changes, relaxation techniques, emotional and spiritual support, and other therapies. You may also receive palliative treatments similar to those meant to get rid of the cancer, such as chemotherapy, surgery, or radiation therapy.
Learn more about the importance of tracking side effects in another part of this guide. Learn more about palliative care in a separate section of this website.
Also Check: Prostate Cancer Lower Back Pain
New Concept Drug Hunts Down Late Stage Prostate Cancer
A new class of drug successfully targets treatment-resistant prostate cancers and prolongs the life of patients. The treatment delivers beta radiation directly to tumour cells, is well tolerated by patients and keeps them alive for longer than standard care, found a phase 3 trial to be presented at the European Association of Urology congress, EAU21, today.
Despite progress in medicine in recent years, metastatic castration-resistant prostate cancer remains untreatable and fatal. The new treatment, known as Lu-PSMA-617, takes a new approach, targeting a molecule called PSMA, which is known to be increased on the surfaces of the tumour cells, destroying them and their surrounding microenvironment.
Professor Johann de Bono, Professor of Experimental Cancer Medicine at The Institute of Cancer Research, London, and Consultant Medical Oncologist at The Royal Marsden NHS Foundation Trust, and Professor Ken Herrmann, Director of the Clinic for Nuclear Medicine at University Hospital Essen, Germany, and an international team of researchers set out to see whether Lu-PSMA-617 was more effective than standard care and recruited 831 patients with metastatic castration-resistant prostate cancer between June 2018 and October 2019. Patients were randomly assigned to receive the treatment plus standard care or standard care alone.
Types Of Treatment For Prostate Cancer
First, lets recap prostate cancer treatment basics, which will depend on a range of factors, including cancer stage and symptoms. Early-stage cancers may be treated with active surveillance, meaning your doctor will closely monitor it to see if it starts to progress before actively treating it. Once treatment begins, it may include a combination of surgery, radiation, and hormone therapy. Advanced prostate cancers may be treated with a combination of hormone therapy, targeted therapy, chemotherapy, immunotherapy, and other drugs. So, whats new in the treatment field?
Read Also: Prostate Cancer Spread To Bones Treatment
Ronald & Victoria Simms Pcf Valor Young Investigator Award
Neil Lin, PhD
University of California, Los Angeles
Mentors: Andrew Goldstein, PhD, Matthew Rettig, MD, Isla Garraway, MD, PhD
Using a Novel 3D Platform to Develop Metabolism-based Prostate Cancer Therapies
Description:
What this means to patients: Cancer cells have a unique metabolism to support their constant and rapid growth. Dr. Lin and team will use a new 3D system to better understand prostate cancer metabolism and will test strategies to kill tumor cells by targeting tumor metabolism. These studies may ultimately lead to new treatments for patients.
Adc For Ovarian Cancer
Robert L. Coleman: The most imminent and important upcoming trial result expected in my field in 2023 is mirvetuximab soravtansine, from ImmunoGen. This received accelerated approval from the US Food and Drug Administration on 14 November, based on results of a single-arm trial that enrolled 106 patients with platinum-resistant ovarian cancer whose tumors had high expression of folate receptor- and who had been treated with up to three prior regimens, at least one of which included bevacizumab .
Under accelerated approval, the sponsor can market their drug under the indication agreed to by the FDA in this case, patients with recurrent, platinum-resistant ovarian cancer. For the drug to move from accelerated approval to regular approval, a confirmatory trial needs to be conducted to confirm the overall safety and efficacy of the agent of interest. In this case, initial results for the confirmatory phase 3 MIRASOL trial are expected in early 2023.
Robert L. Coleman is chief scientific officer at US Oncology Research.
Don’t Miss: Clinical Synergy Complete Prostate Health
More About Darolutamide: New Treatment For Prostate Cancer In 2022
Hormone-sensitive or castration-sensitive prostate cancer means a patient’s tumors are still primarily fueled by male sex hormones . Previously, metastatic hormone-sensitive prostate cancer was treated only with ADT, which blocks the production of androgens by the testicles.
Darolutamide is a new generation of non-steroidal anti-androgen drugs currently being researched to treat prostate cancer. It is an alternative to the current prostate cancer treatment options with a slightly different mechanism of action.
It is a combination of Darolutamide, androgen deprivation therapy, and Docetaxel. For example, Darolutamide works by blocking androgen receptors in cancer cells from binding to androgens . It prevents actions that can allow cancer cells to survive and increase.
Here is the image that depicts the above statement with more clarity.
Internationally, the phase 3 ARASENS trial was randomly done on 1305 patients with newly diagnosed metastatic hormone-sensitive prostate cancer. 86% of the patients were newly diagnosed with prostate cancer spreading to the bones or other organs. All the patients received ADT 12 weeks before the trial and six cycles of Docetaxel starting within 6 weeks after the trial.
- 651 patients received Docetaxel + standard ADT + Darolutamide 600 mg twice daily.
- vs. 654 patients received a matched placebo+ Docetaxel + standard ADT.
John & Daria Barry Pcf Valor Young Investigator Award
Alexandra Sokolova, MD
Oregon Health & Science University
Mentors: Bruce Montgomery, MD, Heather Cheng, MD, PhD
Cascade Genetic Testing in Prostate Cancer: Evaluating and Overcoming Barriers
Description:
What this means to patients: Approximately 12% of patients with metastatic prostate cancer carry heritable mutations that contributed to their disease. Relatives of these patients are encouraged to get genetic testing to determine their own carrier status. Dr. Sokolova and team will develop provider-initiated cascade genetic testing measures as an effort to increase the numbers of family members who get tested, which will ultimately improve cancer prevention in families with inherited cancer syndromes and improve equity and equality in access to cascade genetic testing.
Also Check: What Does Psa Stand For In Prostate Cancer
Anyone On Pluvicto A New Drug For Prostate Cancer
My close friend has had Pluvecto treatment suggested to him by oncologists. It is relatively new, having been approved by the FDA in March 2022. Have any of you been given this drug? I have read it is radioactive material and patient needs to stay away 6 ft from others for at least 3 days so as not to contaminate them. He has not yet decided whether to take the treatment or not as he is feeling awful enough as is.
Hello @royalbee. I noticed you have been part of the discussion on Pluvicto, so you will notice I have moved your most recent post back into this discussion to continue to seek support from this group of members who have experience with this treatment. For reference, you can find your post here: Anyone on Pluvicto , a new drug for prostate cancer?:
Was there any expectations set by the oncologist with regard to what this drug can do for your dad?
Man Given A Year To Live Now Cancer
Further studies under way as remarkable results offer new hope in treating biliary tract cancer
A man given a year to live after being diagnosed with an aggressive form of cancer is now disease-free thanks to a UK trial of a personalised drug regime.
Robert Glynn, 51, a welder from Worsley in Greater Manchester, said he wouldnt be here if it were not for the remarkable results of the immunotherapy trial run by the Christie NHS foundation trust in Manchester.
Glynn was diagnosed with intrahepatic bile duct cancer a day before his 49th birthday in June 2020, after experiencing severe pain in his shoulder, which left him unable to sleep.
Also known as biliary tract cancer, this aggressive condition causes the cells lining the bile ducts to multiply and grow more than they should. Bile ducts are small tubes that connect the liver, gallbladder and small bowel . They release bile into the bowel after eating, helping to digest fat.
I asked my consultant to be honest and tell me how long Id got if I carried on as I was, and she said 12 months, he said.
About 1,000 people in the UK are diagnosed with bile duct cancer every year. For those, like Glynn, whose cancer has spread to other organs, only one in 50 people lived for at least five years after their diagnosis, according to US studies cited by Liver Cancer UK.
Pre-treatment analysis of Glynns tumour showed it had a high mutation burden , suggesting he could have a good response to treatment.
You May Like: Nccn Prostate Cancer Guidelines 2022